. Author manuscript; available in PMC: 2012 May 14.

Published in final edited form as: Lancet Infect Dis. 2010 Jun;10(6):405–416. doi: 10.1016/S1473-3099(10)70079-7

Table 2.

Costs of artemisinin-based combination therapies compared with chloroquine, 2008

Drug	Total dose for full adult course (60kg)	Minimum cost per full adult course (US$)	Additional purchase cost per course (US$)	Additional global purchase cost per year^* (US$)
Artemether-lumefantrine	120mg/720mg	1.474	1.405	98-549 million
Artesunate-amodiaquine	600mg/1836mg	0.918	0.849	60-332 million
Artesunate-mefloquine	600mg/1500mg	3.85	3.781	0.26-1.5 billion
Artesunate- sulfadoxine/pyrimethamine	600mg/2000mg/100mg	1.38	1.311	92-513 million
Dihydroartemisinin-piperaquine^†	135mg/1080mg	1.00	0.931	65-364 million
Chloroquine	1500mg	0.069	-	-

Assumes: a) there are 70-435 million P. vivax infections per year, b) all of these infections are treated, c) adherence to World Health Organization dose recommendations and d) the average total dose administered is 2/3rds of a full adult dose

^†

As DHP is not yet manufactured according to International Good Manufacturing Practice standards, the cost in this table is conservatively set at one US dollar per treatment course based on a predicted public sector price of “less than one US dollar in adults and less than 0.5 US dollars in children” (Duparc, Medicines for Malaria Venture – personal communication).